The IMPOWER-LUNG 1, a phase 3 randomized controlled trial, evaluated patients with advanced NSCLC without EFGR/ALK/ROS1 alterations and with PD-L1 ≥ 50%. The gene discussed is ALK; the disease is non-small cell lung carcinoma.